Zent2U is delighted to announce that we successfully completed the development of a generic version of Descovy® 200 mg/10 mg and 200 mg/25 mg film coated tablets (Gilead Sciences®), based on successful results of bioequivalence studies. 📉
Works on compilation of the respective eCTD dossier have been completed and the dossier is ready for a filing procedure with regulatory authorities in EU within August 2024. 🌍
Emtricitabine and Tenofovir are indicated in combination with other antiretroviral agents for the treatment of adults and adolescents infected with human immunodeficiency virus type 1 (HIV-1). 💊
Having the new dossier in place allows our potential partners to enrich their portfolio of antiretrovirals with a new generic product to offer treatment to growing pool of patients and launch the product in a first wave after patent expiry. 🤝
Partner up now and connect with our team today! 📧
thomas.koene@zentiva.com - Thomas Koene - Head of Zent2U
tomas.pilarcik@zentiva.com – Tomas Pilarcik – Head of B2B Europe
rahul.padhye@zentiva.com – Rahul Padhye – Head of B2B International
nina.fuentes@zentiva.com – Nina Fuentes de Tienda -Key Account Manager B2B Europe
Zent2U B2B innovation generics HIV partnership
